A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 629-638

  Ramaswamy, Bhuvaneswari ^a   Phelps, Mitch A ^b   Baiocchi, Robert ^a   Bekaii Saab, Tanios ^a   Ni, Wenjun ^b   Lai, Ju Ping ^b   Wolfson, Anna ^a   Lustberg, Mark E ^a   Wei, Lai ^b   Wilkins, Deidre ^a   Campbell, Angela ^a   Arbogast, Daria ^a   Doyle, Austin ^c   Byrd, John C ^a   Grever, Michael R ^a   Shah, Manisha H ^a,d  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

CDK inhibitor; Flavopiridol; Phase I trial; Solid tumors

Indexed keywords

COLESTIPOL; COLESTYRAMINE; CYTOKINE; DEXAMETHASONE; FLAVOPIRIDOL; LOPERAMIDE; STEROID; ANTINEOPLASTIC AGENT; FLAVONOID; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BOLUS INJECTION; CANCER PAIN; CLINICAL ARTICLE; COHORT ANALYSIS; CONFUSION; CYTOKINE RELEASE SYNDROME; DEEP VEIN THROMBOSIS; DIAPHORESIS; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUSHING; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXEMIA; ILEUS; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; RIGOR; SIDE EFFECT; SINUS TACHYCARDIA; SOLID TUMOR; SOMNOLENCE; SYNCOPE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR LYSIS SYNDROME; VOMITING; BLOOD; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM; PATHOLOGY; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYTOKINES; FEMALE; FLAVONOIDS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; OHIO; PIPERIDINES; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84860531850     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9563-7     Document Type: Article

References (41)

1. Carlson B, Lahusen T, Singh S et al (1999) Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59:4634-4641
2. Lam LT, Pickeral OK, Peng AC et al (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2: RESEARCH0041
3. Senderowicz AM (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig New Drugs 17:313-320
4. Gojo I, Zhang B, Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527-3538
5. Kitada S, Zapata JM, Andreeff M, Reed JC (2000) Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96:393-397
6. Parker BW, Kaur G, Nieves-Neira W et al (1998) Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91:458-465
7. Bible KC, Kaufmann SH (1996) Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856-4861
8. Drees M, Dengler WA, Roth T et al (1997) Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 3:273-279
9. Patel V, Senderowicz AM, Pinto D Jr et al (1998) Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Investig 102:1674-1681
10. Sambol EB, Ambrosini G, Geha RC et al (2006) Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 66:5858-5866
11. Schwartz GK, Farsi K, Maslak P et al (1997) Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 3:1467-1472
12. Wirger A, Perabo FG, Burgemeister S et al (2005) Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res 25:4341-4347
13. Bible KC, Kaufmann SH (1997) Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57:3375-3380
14. Motwani M, Delohery TM, Schwartz GK (1999) Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5:1876-1883
15. Byrd JC, Peterson BL, Gabrilove J et al (2005) Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. [see comment]. Clin Cancer Res 11:4176-4181
16. Flinn IW, Byrd JC, Bartlett N et al (2005) Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 29:1253-1257
17. Lin TS, Howard OM, Neuberg DS et al (2002) Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 43:793-797
18. Senderowicz AM, Headlee D, Stinson SF et al (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999
19. Thomas JP, Tutsch KD, Cleary JF et al (2002) Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50:465-472
20. El-Rayes BF, Gadgeel S, Parchment R et al (2006) A phase I study of flavopiridol and docetaxel. Investig New Drugs 24:305-310
21. Fornier MN, Rathkopf D, Shah M et al (2007) Phase I dosefinding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 13:5841-5846
22. Schwartz GK, O'Reilly E, Ilson D et al (2002) Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20:2157-2170
23. Tan AR, Headlee D, Messmann R et al (2002) Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20:4074-4082
24. Whitlock JA, Krailo M, Reid JM et al (2005) Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 23:9179-9186
25. Byrd JC, Lin TS, Dalton JT et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404
26. Phelps MA, Lin TS, Johnson AJ et al (2009) Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113:2637-2645
27. Lin TS, Ruppert AS, Johnson AJ et al (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27:6012-6018
28. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
29. CTEP CTEP. Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS Publish date: May 22, 2003.
30. Messmann RA, Ullmann CD, Lahusen T et al (2003) Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res 9:562-570
31. Aklilu M, Kindler HL, Donehower RC et al (2003) Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 14:1270-1273
32. Carvajal RD, Tse A, Shah MA et al (2009) A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology 9:404-409
33. Liu G, Gandara DR, Lara PN Jr et al (2004) A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 10:924-928
34. Schwartz GK, Ilson D, Saltz L et al (2001) Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19:1985-1992
35. Shapiro GI, Supko JG, Patterson A et al (2001) A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7:1590-1599
36. Stadler WM, Vogelzang NJ, Amato R et al (2000) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 18:371-375
37. Blum WPM, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR (2010) Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 95 (7):1098-105, Epub 2010 May 11
38. Rudek MA, Bauer KS Jr, Lush RM 3rd et al (2003) Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 37:1369-1374
39. Lin TS, Blum KA, Fischer DB et al (2010) Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 28:418-423
40. Shah MA, Kortmansky J, Motwani M et al (2005) A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 11:3836-3845
41. Rathkopf D, Dickson MA, Feldman DR et al (2009) Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 15:7405-7411